The Dual Role of Group V Secretory Phospholipase A$_2$ in Pancreatic β-cells

Preetha Shridas[1,2,*], **Victoria P Noffsinger**[1,2], **Andrea C Trumbauer**[1], and **Nancy R Webb**[1,3]

[1]Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington KY 40536

[2]Department of Internal Medicine and University of Kentucky Medical Center, Lexington KY 40536

[3]Pharmacology and Nutritional Sciences, Division of Nutritional Sciences, University of Kentucky Medical Center, Lexington KY 40536

Abstract

Group X (GX) and group V (GV) secretory phospholipase A$_2$ (sPLA$_2$) potently release arachidonic acid (AA) from the plasma membrane of intact cells. We previously demonstrated that GX sPLA$_2$ negatively regulates glucose-stimulated insulin secretion (GSIS) by a prostaglandin E2 (PGE2)-dependent mechanism. In this study we investigated whether GV sPLA$_2$ similarly regulates GSIS. GSIS was significantly decreased in islets isolated from GV sPLA$_2$-deficient (GV KO) mice compared to wild-type (WT) mice. Similarly, GSIS was significantly decreased in MIN6 cells, a murine pancreatic beta cell line with siRNA-mediated GV sPLA$_2$ suppression. MIN6 cells overexpressing GV sPLA$_2$ (MIN6-GV) showed a significant increase in GSIS compared to control cells. The amount of AA released into the media by MIN6-GV cells was significantly higher compared to control cells. However, MIN6-GV cells did not exhibit enhanced PGE2 production or decreased cAMP content compared to control MIN6 cells. Surprisingly, GV KO mice exhibited a significant increase in plasma insulin levels following i.p. injection of glucose compared to WT mice. This increase in GSIS in GV KO mice was associated with a significant increase in pancreatic islet size and number of proliferating cells in β-islets compared to WT mice. Thus, deficiency of GV sPLA$_2$ results in diminished GSIS in isolated pancreatic beta-cells. However, the reduced GSIS in islets lacking GV sPLA$_2$ appears to be compensated by increased islet mass in GV KO mice.

Keywords

To whom correspondence should be addressed: Preetha Shridas, Department of Internal Medicine, 537 CT Wethington Building, 900 South Limestone Street, Lexington 40536, Kentucky, USA. Phone: (859) 323-4933 x81405; Fax: (859) 257-3646; pshri2@uky.edu.

Conflict of Interest: The authors declare that they have no conflict of interest.

Ethical approval: All procedures performed in studies involving mice were in accordance with the guidelines of the University of Kentucky Institutional Animal Care and Use Committees. The article does not contain any studies with human participants performed by any of the authors.

Introduction

Type 2 diabetes (T2D) is increasing at an alarming rate worldwide, largely due to an epidemic of obesity and reduced physical activity. T2D results from chronic insulin resistance that ultimately leads to a progressive decline in pancreatic β-cell function. Although insulin resistance precedes the development of hyperglycemia in subjects that eventually develop T2D, the disease manifests itself in insulin-resistant subjects only with the onset of β-cell dysfunction and reduced β-islet mass [1].

Accumulating evidence indicates that arachidonic acid (AA) and its metabolites play key roles in regulating β-cell function. AA constitutes >30% of the glycerolipid fatty acid mass in rodent islets [2], and stimulation of β-cells with glucose is accompanied by release of free AA. Inhibition of AA release impairs glucose-stimulated insulin secretion (GSIS) [3]. The exact mechanisms linking AA and insulin secretion are not clearly understood. While AA is in general considered to be an activator of GSIS, a major metabolite of AA, prostaglandin E2 (PGE2), is a known inhibitor of GSIS [4-9]. It is believed that PGE2 exerts its effect by interacting with its receptor, EP3, thus decreasing adenylyl cyclase activity with a subsequent reduction in cAMP, a known activator of GSIS [10, 11]. Apart from their effects on GSIS, AA and its metabolites have also been implicated in the regulation of β-cell mass. For example, transgenic overexpression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostanoid biosynthesis including PGE2, resulted in significantly decreased pancreatic β-cell number in mice, leading to a significant increase in blood glucose levels. The reduction in β-cell mass in COX-2 transgenic mice was shown to be due to inhibited β-cell proliferation [12].

The phospholipase A_2 (PLA_2) family comprises a group of intracellular and secreted enzymes that hydrolyze phospholipids to yield free fatty acids and lysophosholipids. This reaction is considered to be the initial, rate-limiting step of AA metabolism leading to the production of bioactive lipids including prostaglandins and leukotrienes. Calcium-independent PLA_2 ($iPLA_2$) enzymes have been implicated in glucose-stimulated AA release. Moreover, inhibition of $iPLA_2β$ using a pharmacological inhibitor, bromoenol lactone suicide substrate, inhibited AA release and GSIS in vitro [3, 13]. Similarly, knockdown of $iPLA_2β$ expression in INS1 cells decreased insulin secretion [14]. Transgenic overexpression of iPLA2β in islet β-cells resulted in enhanced GSIS; consistently, islets from male $iPLA_2β$ -null mice exhibited blunted insulin secretion. The role of cytosolic phospholipase A_2 ($cPLA_2$) in insulin secretion has also been investigated. Overexpression of $cPLA_2$ enhances exocytosis of insulin from β-cells [15]. However, sustained expression of $cPLA_2$ has been reported to upregulate uncoupling protein-2 (UCP-2) and consequent mitochondrial uncoupling, which drastically reduces the capacity of β-cells to respond to nutrients [16]. Consistently, another study documented that overexpression of $cPLA_2$ has no effect on insulin content or the basal rate of insulin secretion, yet negatively effects GSIS, probably due to the prolonged exposure of β-cells to AA [17].

Among the secretory PLA_2 ($sPLA_2$) family members, group IB $sPLA_2$ is reportedly expressed in pancreatic islets of rodents and localized within insulin granules. Stimulation with glucose results in the co-secretion of insulin and group IB $sPLA_2$ [18]. However, the

role of the enzyme in GSIS or pancreatic β-cell function is not known. Recently, we reported that another member of the $sPLA_2$ family, group X $sPLA_2$ (GX $sPLA_2$) is expressed in insulin-producing cells of mouse pancreatic islets and negatively regulates GSIS by enhancing the production of PGE2. Moreover, C57BL/6 mice deficient in GX $sPLA_2$ had increased plasma insulin levels following glucose challenge compared to wild-type mice [19].

Thus, based on available evidence, it appears that during glucose-stimulation, the liberation of AA positively modulates insulin secretion, whereas the generation of AA metabolites such as PGE2 negatively modulates insulin secretion. Therefore, the regulatory effect of individual PLA_2's likely depends on the potency and kinetics of AA/PGE2 production. In this study, we investigated the role of yet another member of the $sPLA_2$ family, group V $sPLA_2$ (GV $sPLA_2$) in pancreatic β-cell function. In vitro studies using artificial phospholipid substrates indicate that GV and GX $sPLA_2$s are the most potent in hydrolyzing phosphatidylcholine [20], the major phospholipid on mammalian cell membranes. However, it is not clear whether these two closely related $sPLA_2$ family members perform redundant physiological functions in vivo.

Materials and Methods

Biochemical Reagents and Assays

Assays for Insulin (Crystal Chem Inc), PGE2 metabolites (Cayman) and cAMP (ENZO Life Sciences) were performed according to the manufacturers' instructions. Phospholipase activity in conditioned media was measured using a colorimetric assay as we previously described [21] with 1-palmitoyl-2-oleoylphosphatidylglycerol (POPG; Matreya LLC) as a substrate. Briefly, mixed micelles were prepared by warming 7 mg of POPG to 37°C in a 0.2 mL mixture of 4.0% (wt/vol) Nonidet-40 and 2.0% sodium deoxycholate, and then adding 1.8 mL warm assay buffer (0.12 mol/L Tris-HCl pH 8, 12 mmol/L $CaCl_2$, 0.1 mmol/L EDTA). For enzyme assays, 10 μL of conditioned media was added to 40 μL of substrate solution. After incubating for 20 minutes at 37°C, the amount of free fatty acids (FFA) released was quantified using a NEFA-C kit (Wako Chemicals); phospholipase activity was calculated as the nmol of FFA released in 20 minutes per mg cell protein.

Animals

GV $sPLA_2$-deficient (GV KO) mice, backcrossed >10 times with C57BL/6 mice, were originally provided by Dr. Jonathan Arm [22]. Mice were maintained on a 10-h light/14-h dark cycle and received standard mouse chow and water *ad libitum.* Male mice were used throughout the study. All procedures were in accordance with the guidelines of the University of Kentucky Institutional Animal Care and Use Committees.

Islet isolation

Mouse islets were isolated via intraductal collagenase (Sigma) digestion and ficoll gradient centrifugation as described earlier [19]. A detailed method will be provided on request. Following isolation, similar-sized islets were selected and hand-picked and maintained in RPMI containing 5 mM glucose, 10% (v/v) FBS and penicillin and streptomycin.

Immunohistochemistry

Pancreata from WT and GV KO mice were embedded in paraffin and 5 μm-thick sections were mounted on glass slides; processing of the tissues on glass slides was done as described earlier [19]. The sections were immunostained using rabbit anti-mouse GV sPLA$_2$ (gift from Dr. M. Gelb, University of Washington) and goat anti-mouse insulin (Santa Cruz Biotechnology), at a dilution of 1:100 for anti-GV sPLA$_2$ and 1:500 for anti-insulin. For fluorescent images, Alexa Fluor-conjugated secondary antibodies were used (Invitrogen). For Ki67 staining, the sections were immunostained using rabbit anti-Ki67 (Abcam,1:150).

β-cell mass, average islet size, and β-cell proliferation

β-cell mass and average islet size were determined as described earlier [23]. Entire pancreata were removed from 4 GV KO and 4 WT mice (16 weeks old), adhering fat tissues as well as other nonpancreatic tissues were removed, and the organ was then weighed and fixed as described above and cut into 5 μm-thick sections. Every 30th section (a total of 7-8 sections per pancreas) was immunostained for insulin, and then imaged under X10 magnification using NIS elements software (Nikon Instruments, Inc.). β-cell mass was calculated by first obtaining the fraction of the total cross-sectional area of the pancreatic tissue immunopositive for insulin and then multiplying the pancreatic weight by this fraction. Average islet size was calculated by dividing the total islet area by the total number of islets analyzed.

The number of nuclei positive for Ki67 within insulin-positive cells was counted to determine β-cell proliferation. Approximately 40 islets from 2 sections per mouse were analyzed in the proliferation assay (n= 3 mice per group).

In vivo GSIS, glucose tolerance and insulin tolerance tests

In vivo GSIS was performed as described earlier [19]. Mice were fasted for 16 h, and then plasma samples were collected from the retro-orbital sinus before and 15 min after *i.p.* glucose injection (3g/kg). For glucose tolerance tests, mice were fasted for 6 h. Blood glucose concentrations were quantified using a glucometer (Contour; Bayer Laboratories) immediately before and 15, 30, 60, 90, and 120 min following intraperitoneal (i.p) administration of glucose (1.5 g/kg body wt). Insulin tolerance was assessed following a 4-h fast by quantifying blood glucose concentrations at 0, 30, 60, 90 and 120 min after administration of human insulin (0.5 U/kg body wt i.p; Novolin, Novo Nordisk).

Cell culture and transfections

MIN6 cells were cultured in complete media (DMEM supplemented with 15% heat-inactivated fetal bovine serum, 2 mmol/l L-glutamine, 45 mmol/l β-mercaptoethanol, 100 units/ml pencillin and 100 μg/ml streptomycin). C-terminal Flag-tagged cDNA for GV sPLA$_2$ was constructed by PCR using forward (F) and reverse (R) primers containing Hind III and EcoRI restriction sites respectively: 5′-TACCCAAGCTTATGAAGGGTCTCCTCACA-3′(F) and 5′-GCGGAATTCTTACTTGTCATCGTCGTCCTTGTAGTCGCAGAGGAAGTTGGG-3′ (R) and mouse GV sPLA$_2$ cDNA as a template. The PCR product was inserted into the mammalian expression vector pcDNA 3.0 (Invitrogen, Carlsbad, CA) to yield a coding

sequence that expressed GV sPLA$_2$ with a C-terminal FLAG epitope tag. DNA sequencing was performed to confirm the integrity of the expression construct. The plasmids were transfected into MIN6 cells using Nucleofector Kit following the manufacturer's instructions and the program T-016 (Nucleofector Kit V; Lonza).

Arachidonic acid (AA) release assay

MIN6 cells transiently transfected with either the "empty" pcDNA 3.0 plasmid (MIN6-C) or the pcDNA3.0 GV sPLA$_2$ expression construct (MIN6-GV) were assayed 24 h after transfection. The transfected cells ($\sim 5 \times 10^5$ cells/well pf 12-well plate) were incubated in 1 ml of complete medium (DMEM medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin) containing 0.1 μCi [^{3}H]arachidonate (200 Ci/mmol; American Radiochemicals Inc, Saint Louis, MO) for 12-16 h. The cells were then washed three times with complete medium followed by 6 h incubation in the same medium. The amount of tritium associated with cells and released into the medium was determined by scintillation counting.

Gene silencing with Small Interfering RNA (siRNA)

A set of pre-designed synthetic oligonucleotides directed to mouse GV sPLA$_2$ (Thermo Scientific, On-TARGETplus SMARTpool siRNA; L-042189-01-0010; mouse PLA2G5 18784) was used. The oligonucleotides were transfected into MIN6 cells using Nucleofector Kit (Nucleofector Kit V; Lonza) and the program T-016. Scrambled siRNA (Thermo Scientific; Non-targeting siRNA#1; D-001810-20) was used as control. The siRNAs were transfected at a final concentration of 2 μg of siRNA pool or non-targeting siRNA per 2×10^6 MIN6 cells. Cells were collected 24 h after transfection for RNA preparation to confirm gene silencing by real-time RT-PCR and used for GSIS assay 48 h after transfection.

Real time RT-PCR

Total RNA was prepared from MIN6 cells using the RNeasy Mini kit (Promega). Quantification was performed in duplicate using the standard curve method and normalized to 18S RNA. The primer sequences used for GV sPLA$_2$ mRNA detection were 5′-AGG GGG CTT GCT AGA ACT CA -3′ (F) and 5′-CAA TCA GTG CCA TCC TTG G -3′ (R).

In vitro insulin secretion assays

In vitro GSIS assays were carried out as described earlier [19]. Briefly, after isolation and handpicking, islets from WT and GV KO mice were cultured overnight in RPMI media. Islets were then selected and transferred to culture inserts (Greiner bio-one) in 12-well plates (25 islets per well), washed, and equilibrated for 1 h in Buffer 1 (DMEM supplemented with 38 mM sodium bicarbonate, 4 mM L-glutamine, 1 mM sodium pyruvate, 4.65 mM HEPES and 1 g/l BSA) containing 5 mM glucose, and then incubated successively for 40 min in Buffer 1 containing 5 mM glucose (low glucose) followed by 40 min in Buffer 1 containing 20 mM glucose (high glucose). At the end of the incubations, insulin content in the low and high glucose-containing buffers was assayed and normalized to total cellular insulin content, which was determined after lysing islets in acid-ethanol (75% ethanol, 0.2 mol/l HCl). To ensure that islets from the two strains of mice were challenged sufficiently to detect

differences in response to glucose, we performed additional *in vitro* GSIS assays in which islets were equilibrated for 1 h in Buffer 1 containing low glucose (1 mM) and then incubated successively for 40 min in Buffer 1 containing physiological glucose (5 mM) followed by 40 min in Buffer 1 containing glucose (20 mM). The impact of GV sPLA$_2$ on GSIS was not different under the two pre-equilibration conditions (data not shown). For GSIS in MIN6-C and MIN6-GV cells, cells (70-80% confluent) in 24-well plates were washed once with Kreb's Ringer buffer containing 0.2% BSA (KRB-BSA) and 5 mM glucose and then equilibrated in the same buffer for 1 h. The media was replaced with fresh KRB-BSA supplemented with either 5 mM (low) glucose or 20 mM (high) glucose for 40 min. Insulin concentrations in conditioned media were normalized to total cell protein.

Statistics

Data are expressed as mean ± SEM. Results were analyzed by *t* test or by 1-way ANOVA followed by a Bonferroni post-test. *P*<0.05 was considered statistically significant. All statistical analyses were carried out using GraphPad Prism 4.

Results

GV sPLA$_2$ is expressed in mouse pancreatic islets

Recently, we reported that group X secretory phospholipase A$_2$ (GX sPLA$_2$) is expressed in pancreatic β-islet cells and negatively regulates insulin secretion through a mechanism mediated by cyclooxygenase-2-dependent prostaglandin E2 production [19]. In this study, we investigated whether a closely related member of the sPLA$_2$ family, group V sPLA$_2$, is expressed and functional in mouse β-islet cells. Double immunofluorescent staining of pancreatic sections from C57BL/6 mice showed positive immunoreactivity for GV sPLA$_2$ (Fig. 1; green staining) that was most intense in regions immunopositive for insulin (red staining), indicating that GV sPLA$_2$ is expressed in insulin-producing β-cells in mouse pancreas (Fig. 1; yellow on merged image). As expected, GV sPLA$_2$ immunoreactivity was not detected in pancreatic sections from GV KO mice (Fig. 1).

GV sPLA$_2$ augments glucose-stimulated insulin secretion (GSIS) in mouse pancreatic β-cell line

GV sPLA$_2$ is known to potentiate the release of arachidonic acid (AA) leading to eicosanoid generation, including PGE2, in several cell types [22, 24]. PGE2 is a negative regulator of glucose-stimulated insulin secretion (GSIS), whereas non-esterified AA is an activator of GSIS [6, 8, 25-28]. Therefore, to assess whether GV sPLA$_2$ regulates GSIS, we investigated the impact of forced overexpression in MIN6 cells, a mouse pancreatic β-cell line that expresses endogenous GV sPLA$_2$ (data not shown). Transient transfection of GV sPLA$_2$ cDNA resulted in a 1.8-fold increase in phospholipase activity secreted into the culture media of MIN6 cells (MIN6-GV) compared to media from cells transfected with control plasmid (MIN6-C; Fig. 2a). Insulin secretion was similar in MIN6-C and MIN6-GV cells incubated in low glucose (5 mM), indicating that overexpression of GV sPLA$_2$ does not impact insulin secretion under basal conditions (Fig. 2b). In contrast, insulin secretion in cells incubated in high glucose (20 mM) was significantly increased in MIN6-GV (2.8±0.19 μg/mg cell protein) compared to MIN6-C (1.95±0.06 μg/mg cell protein; p=0.0015).

Moreover, when expressed as fold-increase over basal, the magnitude of GSIS was significantly greater in cells overexpressing GV sPLA$_2$ (6.4±0.43) compared to control cells (4.8±0.16; p=0.0052; data not shown). The effect of GV sPLA$_2$ overexpression to enhance GSIS occurred in the absence of alterations in total cellular insulin content (Fig. 2c).

GV sPLA$_2$ enhances AA release but not PGE2 production in β-cells

Given the recognized importance of AA and its metabolite, PGE2, in regulating GSIS [6, 8, 27, 28], we next investigated the extent to which GV sPLA$_2$ overexpression enhances AA and PGE2 production in β-cells. MIN6-GV cells demonstrated a modest but significant increase in AA release compared to MIN6-C cells, consistent with GV sPLA$_2$'s known ability to hydrolyze glycerophospholipids on mammalian cell membranes (Fig. 2d) [29]. However, increased AA release was not associated with a significant increase in PGE2 secretion by MIN6-GV cells (Fig. 2e). Moreover, cellular cAMP was not significantly different in MIN6-GV compared to MIN6-C cells (Fig. 2f), as would be expected if enhanced GV sPLA$_2$ activity resulted in increased PGE2 generation. Thus, in contrast to what we observed with GX sPLA$_2$ [19], *it appears that AA released by MIN6 cells through the action of GV sPLA$_2$ is of insufficient magnitude, or is not effectively coupled to the prostaglandin synthetic pathway, to provide a detectable increase in PGE$_2$ production.*

Deficiency of endogenous GV sPLA$_2$ attenuates GSIS in β-cells

To understand the role of endogenous GV sPLA$_2$ in β -cell function, we next investigated the impact of siRNA-mediated silencing on GSIS in MIN6 cells. GV sPLA$_2$ expression was suppressed ~90% in MIN6 cells 24 h after transient transfection with siRNA targeting GV sPLA$_2$ (GV-siRNA; Fig. 3a). While the magnitude of GSIS in GV-siRNA cells (7.03±0.18 μg/mg cell protein) was significantly reduced compared to Scr-siRNA cells (8.8±0.35 μg/mg cell protein; p=0.004), basal insulin secretion was also significantly lower in GV-siRNA cells compared to Scr-siRNA cells (Fig. 3b). As a consequence, the fold-increase in insulin secretion over basal conditions was not significantly different for the two cell lines (6.5±0.16 for GV-siRNA versus 6.1±0.24 for Scr-siRNA).

The lack of a pronounced effect of siRNA-mediated GV suppression on GSIS in MIN6 cells may be the result of residual GV sPLA$_2$ activity in the silenced cells. It is also possible that GV sPLA$_2$ plays a relatively small role in regulating GSIS in this immortalized cell line. Thus, to more definitively assess the impact of endogenous GV sPLA$_2$ on β -cell function, we performed experiments with islets isolated from WT and GV KO mice. To rule out any potential differences in GSIS due to variations in islet size [30], similar-sized islets from WT and GV KO mice were used for the assay. We also confirmed that GX sPLA$_2$ expression was not significantly different in pancreatic islets isolated from GV KO mice compared to WT mice (data not shown). There was no significant difference in basal insulin secretion (5 mM glucose) between islets from WT and GV KO mice (Fig. 3c). As expected, insulin secretion by WT islets increased significantly in response to high glucose (20 mM). Conversely, GSIS was almost totally abolished in islets lacking GV sPLA$_2$ (Fig. 3c). Deficiency of GV sPLA$_2$ in primary islets did not significantly change total insulin content (Fig. 3d), consistent with findings in MIN6 cells (Fig. 2c). Taken together, our results demonstrate that GV sPLA$_2$

enhances GSIS in pancreatic β-cells, in marked contrast to our previous findings with GX sPLA$_2$ [19].

GV KO mice demonstrate enhanced GSIS in vivo

Our *in vitro* findings that GV sPLA$_2$ augments GSIS in cultured MIN6 cells and isolated islets prompted us to investigate the *in vivo* effect of GV sPLA$_2$ deficiency on glucose homeostasis in mice. 6-month-old GV KO mice showed a trend for decreased fasting glucose levels compared to age-matched WT mice (Fig. 4a), which was associated with a non-significant increase in fasting insulin levels in GV KO mice compared to WT (0 min, Fig. 4b). As expected, plasma insulin levels were significantly increased in both WT and GV KO mice 15 minutes after i.p glucose injection (3 mg/kg body weight). Surprisingly, in contrast to *in vitro* and *ex vivo* results, plasma insulin levels 15 min following glucose injection were significantly higher in GV KO mice compared to WT mice (Fig. 4b). Glucose disposal and insulin tolerance were not significantly different between the two strains of mice (Fig. 4c, d), nor was there a significant difference in body weights (data not shown).

GV KO mice have increased average islet size, β-cell mass and proliferation

Despite an apparent defect in GSIS in pancreatic islets that are deficient in GV sPLA$_2$ (Fig. 3c), GV KO mice demonstrated increased GSIS *in vivo* (Fig. 4b). This discrepancy motivated us to investigate potential differences in pancreatic β islets between GV KO and WT mice. Extensive morphometric analysis of pancreatic tissue identified a significant 1.5-fold increase in β-islet mass (estimated by determining the portion of total pancreatic area in tissue sections corresponding to insulin-positive β-islets and the respective pancreatic weights) in GV KO compared to WT pancreas (Fig. 5a). There was no significant difference in pancreatic weights between the two strains (Fig. 5b). Therefore, an increase in β-islet mass must reflect an increase in islet number or an increase in islet size, or both. There was no difference in average number of islets in the pancreas of GV KO mice compared to WT mice (data not shown). However, average islet size was significantly larger for GV KO mice compared to WT mice (Fig. 5c). β-cell proliferation was assessed in pancreatic sections from 12-weeks old WT and GV KO (Fig. 5d shows representative images of GV KO pancreatic section) mice by determining the total number of insulin-positive cells (red staining) that were also positive for Ki67 (green staining) and DAPI nuclear stain. This analysis showed a significant increase in the number of proliferating cells in β-islets in GV KO mice compared to WT (Fig. 5e).

Discussion

There is a large body of evidence pointing to arachidonic acid (AA) and its biologically active metabolites as key regulators of insulin secretion by β-cells [6, 25, 26, 28, 31, 32]. The important role of AA in β-cells is underscored by its relatively high abundance in islets, representing ~30% of the total mass of fatty acyl glycerophospholipids [33]. The liberation of AA from cellular membranes is dependent on the action of PLA$_2$ enzymes, which also represents the initial, rate-limiting step for the production of a myriad of AA-derived bioactive lipid mediators, including prostaglandins and leukotrienes. Despite the central role of PLA$_2$'s in AA metabolism, the relative contributions of the various intracellular and

secreted forms of these enzymes in β-cells and their respective impact on the regulation of insulin secretion has not been fully defined. Thus, we have set out to investigate whether GV or GX sPLA$_2$ play a role in regulating insulin secretion by β-cells. These two related enzymes have been shown to hydrolyze cell membrane phospholipids with much higher efficiency compared to other sPLA$_2$ family members due to their high binding affinity to phosphatidylcholine (PC) [34, 35]. We previously reported that GX sPLA$_2$ suppresses GSIS through a cyclooxygenase-2-dependent mechanism [19]. In this report, we provide evidence that GV sPLA$_2$ regulates β-cell function in a manner that is distinct from GX sPLA$_2$.

Like GX sPLA$_2$, GV sPLA$_2$ is expressed by insulin-producing cells in mouse pancreas and by MIN6 cells, a mouse pancreatic β-cell line. However, in contrast to GX sPLA$_2$, gain and loss of function studies showed that GV sPLA$_2$ enhances GSIS in MIN6 cells. Moreover, primary mouse islet cells deficient in GV sPLA$_2$ exhibit significantly decreased GSIS ex vivo compared to pancreatic islets from wild-type mice. Taken together, our studies demonstrate the unexpected finding that whereas GX sPLA$_2$ expressed by β-cells suppresses GSIS, the related GV sPLA$_2$ enzyme serves to enhance GSIS. It is interesting to note we were unable to detect a significant increase in PGE$_2$ production in MIN6 cells with forced overexpression of GV sPLA$_2$, despite a significant 1.8-fold increase in PLA$_2$ activity secreted by these cells. In comparable studies of GX sPLA$_2$, a 2.2-fold increase in sPLA$_2$ activity in transfected MIN6 cells was associated with a robust 2.5-fold increase in PGE$_2$ generation [19]. The ability of GX sPLA$_2$ to reduce GSIS was blocked in cells treated either with a cyclooxygenase-2 inhibitor or an EP3 receptor antagonist, demonstrating that the suppressive effect of GX sPLA$_2$ is dependent on PGE2 synthesis and signaling through the EP3 receptor. The PGE2-EP3 receptor axis is thought to impact GSIS through decreased adenylyl cyclase activity and consequent reductions in cAMP, an established activator of insulin secretion [10, 11]. Our findings that overexpression of GX sPLA$_2$ [19] but not GV sPLA$_2$ (Fig. 2f), enhances intracellular cAMP concentrations in MIN6 cells is consistent with the conclusion that AA is coupled to increased PGE$_2$ production only in the case of GX sPLA$_2$. We speculate that increased GSIS in GV sPLA$_2$-overexpressing MIN6 cells is a consequence of increased non-esterified AA in these cells, in line with previous studies showing that treatments that increase endogenous AA in β-cells leads to augmented insulin secretion [36]. The mechanisms for AA-mediated activation of GSIS are not totally understood. After glucose-induced depolarization of the plasma membrane and subsequent release of insulin, Kv2.1 channels present on the β-cell membrane serve to repolarize the membrane and consequently limit the duration of insulin secretion [37]. By attenuating Kv2.1 activity, AA prolongs the action potential, resulting in the amplification of GSIS for longer periods [38].

As noted above, our data indicate that AA liberated by GV sPLA$_2$ versus GX sPLA$_2$ has distinct metabolic fates in MIN6 cells, such that GX sPLA$_2$ appears to be uniquely coupled to the prostaglandin synthesis pathway. Several in vitro studies point to differences in subcellular localization and actions for the two enzymes, which might account for our observations in β-cells. Though it is generally believed that GX sPLA$_2$ hydrolyzes phospholipids in the outer leaflet of the plasma membrane, there is evidence that this enzyme may release AA prior to secretion [20]. It has also been suggested that GX sPLA$_2$ is taken up by cells through its high affinity binding to the M-type receptor [39-41], whereas

GV sPLA$_2$ may be internalized and trafficked to intracellular compartments by heparin sulphate proteoglycans [42, 43]. Unlike GV sPLA$_2$, which is expressed as the mature enzyme, GX sPLA$_2$ is originally produced as a proenzyme that must be proteolytically cleaved by furin-like proprotein convertases in order to exert full catalytic activity [44, 45]. Thus, compartmentalization of GX sPLA$_2$ activity may be dictated by the subcellular location of the activating convertase. It is also important to note that local Ca^{2+} concentrations may influence the relative hydrolytic activity of the two enzymes, since in vitro studies indicate the requirement for Ca^{2+} is 10-fold higher for GV sPLA$_2$ compared to GX sPLA$_2$ [46]. Clearly, additional studies are required to determine whether spatial segregation of the catalytic activities of Group V and Group X sPLA$_2$ is responsible for the observed functional differences of these two enzymes in β-cells.

Intriguingly, our in vivo results show that whole-body ablation of GV sPLA$_2$ results in enhanced GSIS in mice (Fig. 4b), contrary to the suppressive effect of GV sPLA$_2$ deficiency observed in isolated islets ex vivo (Fig. 3c). Enhanced GSIS in GV sPLA$_2$-deficient mice was associated with a significant increase in islet mass as well as markers of β-cell proliferation, *which are likely to at least partially overcome* the reduction in GSIS observed for pancreatic islets isolated from GV sPLA$_2$-deficient mice. Recently, Sato et al. reported that diet-induced obesity induces a robust increase in adipocyte expression of GV sPLA$_2$. Additionally, GV sPLA$_2$-deficient mice had significantly increased body weight and greater insulin resistance, mainly in white adipose tissue, compared to wild-type littermates after high fat diet feeding [47]. Interestingly, high fat diet-induced hyperinsulinemia was greater in GV sPLA$_2$-deficient mice compared to wild-type mice, whereas glucose disposal and fasting blood glucose levels were similar for the two strains. The authors also showed that GSIS was significantly more robust in obese GV sPLA$_2$-deficient mice compared to control, although the mechanism for increased GSIS was not investigated. While it is difficult to tease out the systemic versus local effects of GV sPLA$_2$ in β-cell function, our studies in mice fed a normal rodent diet indicate that whole-body GV sPLA$_2$ deficiency is associated with increased β-cell proliferation, an increase in islet mass, and overall capacity to secrete insulin, which may ultimately serve a protective effect in the setting of profound insulin resistance. *The observed effects on β-cell proliferation and islet mass in the GV KO mice may be the consequence of GV sPLA$_2$ deficiency in tissues other than the pancreas. Additional studies using tissue-specific knock-out mice are necessary to fully understand the biology of these intriguing PLA$_2$'s.*

Conclusions

Our results demonstrate that GV sPLA$_2$ plays multiple roles in regulating β-cell function in mice. Based on in vitro studies in MIN6 cells and isolated pancreatic islets, it is clear that GV sPLA$_2$ acts in an autocrine and/or paracrine manner to enhance GSIS, possibly by mediating the release of AA from membrane glycerophospholipids. This activity is in marked contrast to GX sPLA$_2$, which we previously showed suppresses GSIS by providing AA substrate for PGE2 generation in β-cells [19]. The opposing roles of GV and GX sPLA$_2$ in regulating insulin secretion underscore the fact that these two related enzymes are not functionally redundant. Additional in depth studies are necessary to fully understand the biology of these intriguing PLA$_2$'s. Despite the capacity of GV sPLA$_2$ to enhance insulin

secretion by β-cells, the aggregate effect of whole-body GV sPLA$_2$ deficiency was to augment GSIS in mice, an outcome that was associated with increased β-cell proliferation and pancreatic islet mass. These data are consistent with a previous report that GV sPLA$_2$-deficient mice are partially protected from impaired GSIS associated with severe obesity-induced insulin resistance [47]. Thus, GV sPLA$_2$ may provide a potential target for improving β-cell compensation in the setting of insulin resistance.

Acknowledgments

References

1. Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. JClin Invest. 2006; 116:1802–1812. [PubMed: 16823478]

2. Ramanadham S, Gross RW, Han X, Turk J. Inhibition of arachidonate release by secretagogue-stimulated pancreatic islets suppresses both insulin secretion and the rise in beta-cell cytosolic calcium ion concentration. Biochemistry. 1993; 32:337–346. [PubMed: 8418854]

3. Ramanadham S, Song H, Bao S, Hsu FF, Zhang S, Ma Z, Jin C, Turk J. Islet complex lipids: involvement in the actions of group VIA calcium-independent phospholipase A(2) in beta-cells. Diabetes. 2004; 53(Suppl 1):S179–185. [PubMed: 14749285]

4. Robertson RP, Tsai P, Little SA, Zhang HJ, Walseth TF. Receptor-mediated adenylate cyclase-coupled mechanism for PGE2 inhibition of insulin secretion in HIT cells. Diabetes. 1987; 36:1047–1053. [PubMed: 2886385]

5. Sjoholm A. Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta. Biochim Biophys Acta. 1996; 1313:106–110. [PubMed: 8781557]

6. Kimple ME, Keller MP, Rabaglia MR, Pasker RL, Neuman JC, Truchan NA, Brar HK, Attie AD. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013; 62:1904–1912. [PubMed: 23349487]

7. Seaquist ER, Walseth TF, Nelson DM, Robertson RP. Pertussis toxin-sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose-induced insulin secretion in HIT cells. Diabetes. 1989; 38:1439–1445. [PubMed: 2482818]

8. Tran PO, Gleason CE, Poitout V, Robertson RP. Prostaglandin E2 Mediates Inhibition of Insulin Secretion by Interleukin-1β. J Biol Chem. 1999; 274:31245–31248. [PubMed: 10531320]

9. Fujita H, Kakei M, Fujishima H, Morii T, Yamada Y, Qi Z, Breyer MD. Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice. Biochem Biophys Res Commun. 2007; 363:37–43. [PubMed: 17825788]

10. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. JLipid Res. 2009; 50:S423–S428. [PubMed: 19095631]

11. Yajima H, Komatsu M, Schermerhorn T, Aizawa T, Kaneko T, Nagau M, Sharp GW, Hashizume K. cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets. Diabetes. 1999; 48:1006–1012. [PubMed: 10331404]

12. Oshima H, Taketo MM, Oshima M. Destruction of Pancreatic β-Cells by Transgenic Induction of Prostaglandin E2 in the Islets. J Biol Chem. 2006; 281:29330–29336. [PubMed: 16873378]

13. Song K, Zhang X, Zhao C, Ang NT, Ma ZA. Inhibition of Ca^{2+}-independent phospholipase A2 results in insufficient insulin secretion and impaired glucose tolerance. Mol Endocrinol. 2005; 19:504–515. [PubMed: 15471944]

14. Bao S, Bohrer A, Ramanadham S, Jin W, Zhang S, Turk J. Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J Biol Chem. 2006; 281:187–198. [PubMed: 16286468]

15. Juhl K, Hoy M, Olsen HL, Bokvist K, Efanov AM, Hoffmann EK, Gromada J. cPLA2alpha-evoked formation of arachidonic acid and lysophospholipids is required for exocytosis in mouse pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2003; 285:E73–81. [PubMed: 12644445]

16. Milne HM, Burns CJ, Squires PE, Evans ND, Pickup J, Jones PM, Persaud SJ. Uncoupling of nutrient metabolism from insulin secretion by overexpression of cytosolic phospholipase A(2). Diabetes. 2005; 54:116–124. [PubMed: 15616018]

17. Jones PM, Burns CJ, Belin VD, Roderigo-Milne HM, Persaud SJ. The role of cytosolic phospholipase A_2 in insulin secretion. Diabetes. 2005; 53:S172–S178.

18. Ramanadham S, Ma Z, Arita H, Zhang S, Turk J. Type IB secretory phospholipase A2 is contained in insulin secretory granules of pancreatic islet β-cells and is co-secreted with insulin from glucose-stimulated islets. Biochim Biophys Acta. 1998; 1390:301–312. [PubMed: 9487151]

19. Shridas P, Zahoor L, Forrest KJ, Layne JD, Webb NR. Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism. J Biol Chem. 2014; 289:27410–27417. [PubMed: 25122761]

20. Mounier CM, Ghomashchi F, Lindsay MR. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha. J Biol Chem. 2004; 279:25024–25038. [PubMed: 15007070]

21. Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJS, Webb NR. Group V sPLA2 Hydrolysis of Low-Density Lipoprotein Results in Spontaneous Particle Aggregation and Promotes Macrophage Foam Cell Formation. Arterioscler Thromb Vasc Biol. 2004; 24:762–767. [PubMed: 14962950]

22. Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem. 2004; 279:16488–16494. [PubMed: 14761945]

23. Shoemaker R, Yiannikouris F, Thatcher S, Cassis L. ACE2 deficiency reduces beta-cell mass and impairs beta-cell proliferation in obese C57BL/6 mice. Am J Physiol Endocrinol Metab. 2015; 309:E621–631. [PubMed: 26389599]

24. Shinohara H, Balboa MA, Johnson CA, Balsinde J, Dennis EA. Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s. J Biol Chem. 1999; 274:12263–12268. [PubMed: 10212194]

25. Meng ZX, Sun JX, Ling JJ, Lv JH, Zhu DY, Chen Q, Sun YJ, Han X. Prostaglandin E2 regulates Foxo activity via the Akt pathway: implications for pancreatic islet beta cell dysfunction. Diabetologia. 2006; 49:2959–2968. [PubMed: 17033838]

26. Meng Z, Lv J, Luo Y, Lin Y, Zhu Y, Nie J, Yang T, Sun Y, Han X. Forkhead Box O1/Pancreatic and Duodenal Homeobox 1 Intracellular Translocation Is Regulated by c-Jun N-Terminal Kinase and Involved in Prostaglandin E2-Induced Pancreatic β-Cell Dysfunction. Endocrinology. 2009; 150:5284–5293. [PubMed: 19837872]

27. Landt M, Easom RA, Colca JR, Wolf BA, Turk J, Mills LA, McDaniel ML. Parallel effects of arachidonic acid on insulin secretion, calmodulin-dependent protein kinase activity and protein kinase C activity in pancreatic islets. Cell calcium. 1992; 13:163–172. [PubMed: 1315620]

28. Metz SA. Exogenous arachidonic acid promotes insulin release from intact or permeabilized rat islets by dual mechanisms. Putative activation of Ca^{2+} mobilization and protein kinase C. Diabetes. 1988; 37:1453–1469. [PubMed: 3141235]

29. Balboa MA, Balsinde J, Winstead MV, Tischfield JA, Dennis EA. Novel group v phospholipase A_2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J Biol Chem. 1996; 271:32381–32384. [PubMed: 8943302]

30. Reaven EP, Gold G, Walker W, Reaven GM. Effect of variations in islet size and shape on glucose-stimulated insulin secretion. Horm Metab Res. 1981; 13:673–674. [PubMed: 7033094]

31. Jones PM, Persaud SJ. Arachidonic acid as a second messenger in glucose-induced insulin secretion from pancreatic β-cells. J Endocrinol. 1993; 137:7–14. [PubMed: 8492079]

32. Luo P, Wang MH. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat. 2011; 95:1–10. [PubMed: 21757024]

33. Ramanadham S, Bohrer A, Mueller M, Jett P, Gross RW, Turk J. Mass spectrometric identification and quantitation of arachidonate-containing phospholipids in pancreatic islets: Prominence of plasmenylethanolamine molecular species. Biochemistry. 1993; 32:5339–5351. [PubMed: 8499439]

34. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, Sadilek M, Nguyen E, Lazdunski M, Lambeau G, Gelb MH. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem. 2002; 277:48535–48549. [PubMed: 12359733]

35. Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G. On the diversity of secreted phospholipases A(2). Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J Biol Chem. 1999; 274:31195–31202. [PubMed: 10531313]

36. Persaud SJ, Muller D, Belin VD, Kitsou-Mylona I, Asare-Anane H, Papadimitriou A, Burns CJ, Huang GC, Amiel SA, Jones PM. The Role of Arachidonic Acid and Its Metabolites in Insulin Secretion From Human Islets of Langerhans. Diabetes. 2007; 56:197–203. [PubMed: 17192482]

37. Jacobson DA, Weber CR, Bao S, Turk J, Philipson LH. Modulation of the pancreatic islet beta-cell-delayed rectifier potassium channel Kv2.1 by the polyunsaturated fatty acid arachidonate. J Biol Chem. 2007; 282:7442–7449. [PubMed: 17197450]

38. Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammala CE, Philipson LH. Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. Cell metab. 2007; 6:229–235. [PubMed: 17767909]

39. Rouault M, Le Calvez C, Boilard E, Surreal F, Singer A, Ghomashchi F, Bezzine S, Scarzello S, Gelb MH, Lambeau G. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry. 2007; 46:1647–1662. [PubMed: 17279628]

40. Morioka Y, Saiga A, Yokota Y, Suzuki N, Ikeda M, Ono T, Nakano K, Fujiii N, Ischizaki J, Arita H, Hanasaki K. Mouse group x secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 Receptor. Arch Biochem Biophy. 2000; 381:31–42.

41. Yokota Y, Higashino K, Nakano K, Arita H, Hanasaki K. Identification of group X secretory phospholipase A(2) as a natural ligand for mouse phospholipase A(2) receptor. FEBS Lett. 2000; 478:187–191. [PubMed: 10922494]

42. Rosengren B, Peilot H, Umaerus M, Jonsson-Rylander AC, Mattsson-Halten L, Hallberg C, Cronet P, Rodriquez-Lee M, Hurt-Camejo E. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol. 2006; 26:1579–1585. [PubMed: 16601231]

43. Murakami M, Koduri RS, Enomoto A, Shimbara S, Seki M, Yoshihara K, Singer A, Valentin E, Ghomashchi F, Lambeau G, Gelb MH, Kudo I. Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J Biol Chem. 2001; 276:10083–10096. [PubMed: 11106649]

44. Layne JD, Shridas P, Webb NR. Ectopically expressed pro-group X secretory phospholipase A2 is proteolytically activated in mouse adrenal cells by furin-like proprotein convertases: implications for the regulation of adrenal steroidogenesis. J Biol Chem. 2015; 290:7851–7860. [PubMed: 25623068]

45. Jemel I, Ii H, Oslund RC, Payre C, Dabert-Gay AS, Douquet D, Charqui K, Scarzello S, Gelb MH, Lambeau G. Group x secreted phospholipase A$_2$ proenzyme is matured by a furin-like proprotein convertase and releases arachidonic acid inside of human HEK293 cells. J Biol Chem. 2011; 286:36509–36521. [PubMed: 21878635]

46. Kamitani S, Yamada K, Yamamoto S, Ishimoto Y, Ono T, Saiga A, Hanasaki K. Differences between group x and group v secretory phospholipase A(2) in lipolytic modification of lipoproteins. Cell Mol Biol Lett. 2012; 17:459–478. [PubMed: 22706677]

47. Sato H, Taketomi Y, Ushida A, Isogai Y, Kojima T, Hirabayashi T, Miki Y, Yamamoto K, Nishito Y, Kobayashi T, Ikeda K, Taguchi R, Hara S, Ida S, Miyamoto Y, Watanabe M, Baba H, Miyata K,

Oike Y, Gelb MH, Murakami M. The adipocyte-inducible secreted phospholipases PLA$_2$G5 and PLA$_2$G2E play distinct roles in obesity. Cell metab. 2014; 20:119–132. [PubMed: 24910243]

Fig 1.
GV sPLA$_2$ is expressed in mouse pancreatic islet cells. Pancreatic sections from WT and GV KO mice were co-stained by indirect immunofluorescence for GV sPLA$_2$ (green) and insulin (red) and visualized (20 × magnification) by fluorescence microscopy. A merged image shows expression of GV sPLA$_2$ in insulin-producing cells of WT pancreas (yellow).

Fig 2.
GV sPLA$_2$ activates glucose-stimulated insulin secretion (GSIS) and enhances AA release in MIN6 cells. MIN6 cells were transfected with a control expression plasmid (MIN6-C) or an expression plasmid encoding GV sPLA$_2$ (MIN6-GV) as described under "Materials and Methods." a, Phospholipase activity in 48 h conditioned media from MIN6-C or MIN6-GV cell cultures was determined and normalized to cell protein. b, GSIS was performed in MIN6-C and MIN6-GV cells 48 h after transfection as described in "Materials and Methods." Insulin levels in the media were determined and normalized to total cell protein. c, Total cellular insulin content of MIN6-C and MIN6-GV cells was assessed as described in "Materials and Methods." d, [^{3}H]-AA release by MIN6-C and MIN6-GV cells was quantified and expressed as the percent of total cellular [^{3}H]-AA as described in "Materials and Methods." e, PGE2 levels in culture media from MIN6-C and MIN6-GV cells 48 h after transfection, normalized to total cell protein. f, cellular cAMP content in MIN6-C and MIN6-GV cells was determined 48 h after transfection and normalized to total cell protein. Data are from 4 independent transfections per construct and are presented as mean ± S.E; *p<0.05. ***, p < 0.001.

Fig 3.

GV sPLA$_2$ deficiency suppresses GSIS in MIN6 cells and primary mouse pancreatic islet cells. MIN6 cells were transfected with a control siRNA (Scr-siRNA) or siRNA directed to GV sPLA$_2$ (GV-siRNA), as described under "Materials and Methods." a, RNAs were prepared from Scr-siRNA and GV-siRNA cells 24 h after transfection for quantification of GV sPLA$_2$ mRNA abundance. b, GSIS was performed in Scr-siRNA cells and GV-siRNA cells as described in "Materials and Methods." Insulin secreted into the media was assayed and normalized to total cell protein. c, GSIS assay was performed using islets (25 similar-sized islets per mouse) isolated from 4-month-old WT and GV KO mice (n=4). Islets were incubated successively for 40 min in buffer containing 5 mM glucose (low glucose) and for 40 min in buffer containing 20 mM glucose (high glucose). Insulin in the assay media was determined and normalized to total cellular insulin in the corresponding islets. d, Total islet insulin content in 25 similar-sized islets from WT and GV KO mice were estimated and normalized to total protein. Data are presented as mean ± S.E; ns-not significant; **p<0.01;***p<0.001.

Fig 4.

Enhanced in vivo GSIS in GV KO mice. a, Blood glucose levels after 16 h fast in WT and GV KO mice. b, Plasma insulin levels were determined before and 15 min after i.p. glucose injection (3 g/kg; n=4-5) in 6-month old WT and GV KO mice. c, 6- month old WT and GV KO mice were fasted for 6 h prior to i.p. injection of 1.5 mg glucose/g body weight, and glucose concentrations in the blood were determined at the indicated time after injection (n=5). d, 6- month old WT and GV KO mice were fasted for 4 h prior to i.p. glucose injection of human insulin (0.5 U/kg body weight), and glucose concentrations in the blood were determined at the indicated time after injection (n=4-5). e, body weight of WT and GV KO mice (n=4/strain). Data are presented as mean ± S.E; ***p<0.001.

Fig 5.
Increased β-islet mass, average islet size and β-cell proliferation in the pancreas of GV KO mice. a, Pancreatic β-islet mass of WT and GV KO mice (n=4/strain; 5-8 sections were analyzed from each mouse) were calculated by obtaining the fraction of the area of pancreatic tissue positive for insulin staining and multiplying this by the pancreatic weight as described in detail in the "Materials and Methods." b, Pancreatic weight of WT and GV KO mice (n=4/strain). c, Average islet size of WT and GV KO pancreata (n=4/strain; 5-8 sections/mouse) was calculated by dividing the total area of pancreatic tissue positive for insulin staining by the total number of islets. d, Representative immunofluorescence images of pancreatic islets from GV KO mice at 20X magnification showing insulin (red) and Ki67 (indicated by arrows pointing to green staining). A merged image shows expression of Ki67 in insulin-producing cells of GV KO pancreas, co-localized with DAPI staining. e, Quantification of number of β-cells with Ki67-positive nuclei per 100 islets in WT and GV KO mice (n=3/group; 30-50 islets from 2 sections per mouse). Data are presented as mean ± S.E; *p<0.05; ***p<0.01.